mash wegovy - Search News

Order byBest matchMost fresh

Novo Nordisk, MAS

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

BioPharma Dive · 1d

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Investor's Business Daily on MSN · 17h

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Pharm Exec · 22h

Novo Nordisk’s Soar Grows Following Accelerated Approval of Wegovy for MASH and Liver Fibrosis

Wegovy's new indication for noncirrhotic MASH with liver fibrosis is the first GLP-1 receptor agonist approved for this condition.

· 1d

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

· 1d

Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH

20h

A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising.

Medscape1d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.

Zacks.com on MSN2h

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.

Health and Me on MSN11h

Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated steatohepatitis (MASH) in adults. Know how the approval was given and what it means for Wegovy's future as a weightloss and diabetes drugs.